Browse

Welcome back to another edition of Endpoints Weekly! We’re in the dog days of summer, but we still have some big stories to recap for you this weekend. Let’s break it down. Despite keeping Robert ...

Biogen announced that its monoclonal antibody felzartamab has received regulatory clearance in China for use in patients with multiple myeloma who have already received first-line therapy. The app…